Copyright
©2014 Baishideng Publishing Group Inc.
World J Methodol. Jun 26, 2014; 4(2): 59-72
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.59
Published online Jun 26, 2014. doi: 10.5662/wjm.v4.i2.59
miRNAs | Target | Drug/ Treatment | R/S | Ref. |
miR-9, let-7g | NFκB1 | Radiotherapy | S | [66] |
miR-34b | BCL2 | Radiotherapy | S | [67] |
miR-214 | N/A; PTEN | Radiotherapy; gefitinib | R | [68,88] |
miR-155 | FOXO3A; Apaf-1 | Radiotherapy; cisplatin | R | [69,78] |
miR-210 | Stabilizes HIF-1A in normoxia | Radiotherapy | R | [70] |
miR-181 | N/A | Cisplatin | S | [72] |
miR-451 | N/A | Cisplatin | S | [73] |
miR-98 | TP53 | Cisplatin | R | [74] |
miR-497 | BCL2 | Multiple drugs | S | [75] |
miR-200b | BCL2, XIAP; E2F3 | Cisplatin; docetaxel | S | [76,86] |
miR-21 | PTEN, BCL2 | Cisplatin | R | [79] |
miR-135a | APC | Paclitaxel | R | [82] |
miR-100 | Plk1 | Docetaxel | S | [85] |
miR-337-3p | STAT3, RAP1A | Paclitaxel and | S | [87] |
docetaxel | ||||
miR-221, miR-222 | P27kip1 | TRAIL | R | [91] |
miR-130a | MET | TRAIL | S | [92] |
miR-212 | PED | TRAIL | S | [93] |
Traditional Procedures | Possible microRNA biomarkers | |
Diagnosis | ||
Detect abnormalities | X-ray, CT scan | 21 |
Confirm malignancy | Biopsy, sputum/fluid cytology | let-7, 29a, 34c, 205, 375 |
Prognosis | ||
Staging | CT scan, PET, MRI | 21, 125b, 155, 182/183 |
Mutational status | Sequencing, PCR, microarray | 21, 155 |
Treatment | Potential prognostic biomarkers | Potential role in resistance |
Surgery | Let-7, 21 | |
Radiotherapy | 155, 210 | Let-7g, 9, 34, 155, 210, 214 |
Chemotherapy | 21, 125b | 21, 30b/c, 98, 100, 103, 130a, 135a, 155, 181, 200b, 203, 212, 214, 221/222, 337, 451, 453, 494, 630 |
- Citation: Joshi P, Middleton J, Jeon YJ, Garofalo M. MicroRNAs in lung cancer. World J Methodol 2014; 4(2): 59-72
- URL: https://www.wjgnet.com/2222-0682/full/v4/i2/59.htm
- DOI: https://dx.doi.org/10.5662/wjm.v4.i2.59